What changed
$QGEN — BUY 📊
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
🎯 Q1 FY26 | EPS $0.54 vs $0.54 ➖
💡 Consensus estimates barely model organic non-COVID revenue growth above low single digits, reflecting a 'show-me' stance after COVID unwind. In contrast, our channel checks and product cycle analysis point to accelerating QuantiFERON/TB testing, QIAstat menu expansion, and NeuMoDx placements that can drive mid-single-digit organic growth and...
📉 Reward/Risk: 2.5:1
🏢 Business Quality: 7/10
📊 Valuation: fair — at $37.22, QGEN trades at 17.2x annualized Q1 EPS, which is at the lower end of the 15-25x peer range for diversified life science...
🔮 Catalyst: Next quarterly earnings release (Q2 2026)
💰 Entry: $37.0, stop $35.0, target $42.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/QGEN0617